SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF A NEW SERIES OF CEPHALOSPORINS, BMY-28142 AND RELATED COMPOUNDS
TAKAYUKI NAITO*, SHIMPEI ABURAKI, HAJIME KAMACHI, YUKIO NARITA, JUN OKUMURA and HIROSHI KAWAGUCHI Bristol-Myers Research Institute, Ltd., Tokyo Research Center, 2-9-3 Shimo-meguro, Meguro-ku, Tokyo 153, Japan (Received for publication April 2, 1986) The synthesis of a series of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-oxyiminoacetamido]-3-ammoniomethyl-3-cephems is described. Variations of an oxyimino moiety in the 7-side chain and a quaternary ammonium moiety in the 3-side chain were examined and structure-activity relationships studied. BMY-28142, the 3-(N-methylpyrrolidinio)methyl derivative of the 7-a-methoxyimino series of cephalosporins, exhibited broad antimicrobial activity against both Gram-positive and Gram-negative bacteria including Pseudoinonas aeruginosa.
Many of the recently introduced cephalosporins
have a common structural feature in that they have a 2-aminothiazolylacetamido group in the 7-side chain with an a-oxyimino substitution. These include cefotaximel-3), ceftizoxime4,5), cefinenoxime6), ceftriaxone7,8) and ceftazidimea 9-11) which are characterized by their excellent activity against Enterobacteriaceae. They are, however, relatively weak in anti-staphylococcal activity as compared to older cephalosporins such as cephalothin and cefazolin.
Among the new family of cephalosporins, only ceftazidime exhibits a potent anti-pseudomonal activity, but unfortunately it is less active than other members of this group of cephalosporins against Staphylococci.
Our primary target in the present work was to obtain ceftazidime analogs with improved antistaphylococcal activity while retaining high anti-pseudomonal activity. Modifications by replacing the pyridinium group of ceftazidime with an aliphatic ammonium group gave compounds with excellent Gram-negative activity though they were only weakly active against Staphylococci. Substantial improvement in anti-staphylococcal activity was achieved by replacing the 2-carboxy-2-propoxyimino group in the 7-side chain with an alkoxyimino substitution. Thus, a series of the 7-aalkoxyimino derivatives having a quaternized ammonium group in the 3-side chain were prepared.
Among them, 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-(1-methylpyrrolidinio)-
methyl -3 -cephem -4 -carboxylate, designated BMY-28142, was found to be most promising in view of its antimicrobial spectrum and other biological properties12-21).
This paper describes the synthesis and the structure-activity relationships of BMY-28142 and analogs'. Detailed microbiological evalua- tion of BMY-28142 will be reported in a separate paper 12).
Synthesis
Preparation of the 7-a-oxyimino derivatives having a quaternary ammonium group in the 3-side chain was performed according to the procedure illustrated in Scheme 1. The starting material, diphenylmethyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (11)24), was acylated with (Z)-2-(substituted-oxyimino)-2-(2-tritylaminothiazol-4-yl)acetic acid, la 25) or Ib-f26), by the acid chloride method using PCl5 to afford the 3-chloromethyl derivative (IIIa -f), which was converted to the corresponding iodide (IVa-f).
The 2-carboxy-2-propoxyimino derivatives (ceftazidime analogs) having a quaternary alicyclic ammonium group at the 3-side chain were prepared from the key intermediate IVa by Method A of Scheme 1 by quaternization with a tertiary amine, followed by deblocking and purification by HPLC.
These derivatives are shown in Table 1 .
On the other hand, three methods (Methods A, B and C of Scheme 1) were employed for the preparation of 7-a-methoxyimino derivatives listed in Table 2 . In Method A, the key intermediate IVb was treated with tertiary aliphatic or alicyclic amines of Group A-1, A-2 or A-3 in Table 3 to give the quaternized ammonium derivatives (Vb), which was deblocked and purified by HPLC to afford the desired d3 isomer of the final products (VIb) in 4-42% overall yield from IVb. Formation of a considerable amount of the d2 isomer was observed during the quaternization step. The isomer was removed by HPLC at the final stage.
When tertiary amines of Groups A-2 and A-3 in Table 3 were used for introduction of the quaternary side chain, an additional asymmetric center was generated on the quaternary nitrogen and the final products were obtained as mixtures of diastereomers. The isomers having Group A-2 amines Table 1 . Yield, mp, IR and 1H NMR data of 2-carboxy-2-propoxyimino derivatives (I -6). Table 2 ), although the stereochemistry of the quaternary nitrogen of the isomers was not determined. The products from Group A-3 amines (24 and 28) were characterized as mixtures of the diastereomers.
In Method B (Scheme 1) the iodide IVb was first treated with secondary amines (Group B of Table 3 ) to give the tertiary amino derivatives (VIIb), which were then quaternized with an appropriate alkyl iodide to afford Vb. This method was applied for the preparation of 7, 9, 21 and 31 in Table 2 with no advantages in terms of yield and 43/42 ratio.
Method C in Scheme 1 was used in an attempt to minimize the formation of the 42 isomer. The key intermediate IVb was oxidized with m-chloroperbenzoic acid and then treated with tertiary amines of Group C in Table 3 to afford the quaternized sulfoxide (IXb) in a good yield. Reduction of the sulfoxide IXb was carried out by addition of potassium iodide and acetyl chloride, followed by quenching with sodium metabisulfite to afford Vb as a single isomer. Although no 42 isomer was detected in this method, the reaction was rather sluggish requiring a tedious purification procedure at the final stage. Employment of other reducing agents (e.g. PBr3 etc.) or work-up by other procedures resulted in a complex mixture or contamination of 42 isomer in the product.
Another method shown in Scheme 2 was explored for the bulk preparation of BMY-28142, the representative compound of this series. In contrast to the above-described methods, this procedure Modification in the methoxyimino moiety of BMY-28142 was also accomplished by Method A using an appropriate 3-iodomethyl derivative (IVc-f). Table 4 shows the derivatives of this group prepared in this study.
Antimicrobial Activity
The minimum inhibitory concentrations (MICs) of the cephalosporins of this series were determined by two-fold serial agar dilution method in Mueller-Hinton agar against 32 test organisms which are classified into 6 groups as shown in Table 5 . The in vitro activity of cephalosporins in the primary evaluation was assessed by the geometric mean of MICs of a compound for each group of the test organisms. Results are shown in Tables 6, 7 and 8. Table 6 shows in vitro activity of 2-carboxy-2-propoxyimino derivatives (ceftazidime analogs). Table 6 . In vitro antibacterial activity of 2-carboxy-2-propoxyimino derivatives (1 -6). a See Table 5 . Replacement of the 3-pyridinium group of ceftazidime by alicyclic ammonium groups caused a decrease of the activity against both groups of Staphylococci, Gp-Ia and Gp-Ib. As compared to ceftazidime, compounds 1 and 2 showed somewhat better activity against Gram-negative organisms (Gn-Ia, Gn- Table  5 . Ib and Gn-II) except Pseudornonas aeruginosa (Gn-III), which was more susceptible to ceftazidime .
Compounds 3 through 6 derived from 6-membered amines were less active than ceftazidime against most groups of the test organisms. Table 7 shows the in vitro activity of 27 derivatives of the a-methoxyimino series (compounds 7 through 33). Most of them are similar to each other in the spectrum with a markedly improved antistaphylococcal activity over ceftazidime. Furthermore, they showed high Gram-negative activity especially against cephalothin-resistant Enterobacteriaceae (Gn-Ib and Gn-II), as compared to ceftazidime. They were somewhat less active than ceftazidime against P. aeruginosa. Compound 7, designated BMY-28142, was selected as a ]-.ad compound in this series in view of its well-balanced activity profile. Table 8 shows the geometric mean of MICs of four analogs of BMY-28142 (7) (compounds 34 through 37), in which the methoxyimino moiety of 7 was modified. The ethoxyimino analog (34) was somewhat more active (x I -2) than 7 against Staphylococcus aureus species, but less active (x 1 /2 -1/4) against Gram-negative organisms. Other derivatives (35 -37) were also more active than 7 against Gp-la, but none of them exceeded the activity of 7 against Gram-negative strains including P. aeruginosa.
Experimental
Melting points were determined with a Yanagimoto micro hot-stage apparatus and are uncorrected. IR spectra were recorded on Jasco IRA-1 and UV spectra on Shimadzu UV-200 spectrophotometer. NMR spectra were recorded on a Jeol CL-60HL or on a Varian FT-80A spectrometer.
3-Chloromethyl Derivatives, III. General Procedure Illustrated with the Preparation of Diphenylmethyl 3-Chloromethyl-7-[(Z)-2-methoxyimino-2-(2-tritylam inothiazol-4-yl)acetam ido]-3 -cephem-4-carboxylate (IIIb)
Diphenylmethyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (II)74) (2.29 g, 5.07 mmol) in acetonitrile (57 ml) was treated with N,O-bis(trimethylsilyl)acetamide (4.09 ml, 16.6 mmol) at room temp for 50 minutes to give a clear solution. To the solution was added an acid chloride solution, which was prepared from (Z)-2-methoxyimino-2-(2-tiitylaminothiazol-4-yl)acetic acid (Ib)28> (2.04 g, 4.60 mmol) and phosphorous pentachloride (1.15 g, 5.52 mmol) in CH2Cl2 (20 ml). The mixture was stirred at room temp for 30 minutes, poured into cold H2O (200 ml) and extracted with EtOAc (3 x 100 ml). The combined extracts were washed with aq NaCl, dried and evaporated. The residual syrup (4 g) was chromatographed on a silica gel (150 g) column by eluting with 10: 1 and 3:1 mixtures of toluene and EtOAc, successively. The fractions containing the desired compound were combined and evaporated to afford 2.61 g (74%) of IIlb as an amorphous powder: MP 130°C; IR vh,R cm-1 1780, 1720, 1670; 1H NMR (60 MHz, CDCl3) 6 3.50 (2H, s, 2-H 
3-lodomethyl Derivatives, IV. General Procedure Illustrated with the Preparation of Diphenylmethyl 3-Iodomethyl-7-[(Z)-2-methoxyimino-2-(2-tritylaminothiazol-4-yl)acetamido]-3-cephem-4-carboxylate (IVb)
A mixture of the 3-chloromethyl derivative (IIIb) (1.50 g, 1.79 mmol) and NaI (1.34 g, 8.93 mmol) in methyl ethyl ketone (30 ml) was stirred at room temp for 1 hour. After evaporation of the solvent, the residue was dissolved in EtOAc (100 ml) and washed with H2O, aq Na2S2O3 and aq NaCl, dried and evaporated to give the title compound IVb (1.47 g, 89%) , as an amorphous powder: MP 120°C 3-Quaternary Cephalosporins (VI in Scheme 1) Introduction of the quaternary side chain to the 3'-position was accomplished by quaternization of the iodide (IV) with tertiary amines (Method A), by reaction of IV and secondary amines followed by quaternization with alkyl iodides (Method B) or by oxidation to the 1-oxide (VIII), quaternization with tertiary amines and subsequent reduction of the 3-quaternized 1-oxides (IX) (Method C). Amines used in these three methods are shown in Table 3 .
The preparation procedures of BMY-28142 by Methods A, B and C (Scheme 1) are described as representative examples for 3-quaternized cephalosporins prepared in this study. The physical data of the 2-carboxy-2-propoxyimino (1-6), methoxyimino (7-33) and alkoxyimino (34-37) derivatives are listed in Tables 1, 2 and 4, respectively.
Method A: To a suspension of the 3-iodomethyl derivative (IVb, 5.0 g, 5.37 mmol) in ether (500 ml) was added N-methylpyrrolidine (915 mg, 11.5 mmol) and the mixture was stirred for 1 hour at room temp. The resulting precipitate was collected by filtration, washed with ether (2 x 100 ml) and dried in vacuo to give the quaternized product Vb (3.38 g). From the filtrate, the second crop of Vb (610 mg A 3.99-g sample of Vb obtained above was treated with 90% trifluoroacetic acid (TFA, 20 ml) for 1 hour at room temp, and then evaporated in vacuo. The residue was triturated with ether (200 ml) to give 3.03 g of the TFA salt of 7, which was found to be a 2.6: 1 mixture of the d3 and d2 isomer [determined by HPLC: Lichrosorb RP-18, MeOH -0.01 M phosphate buffer (pH 7), 15:85] . A solution of the TFA salt of 7 in MeOH (5 ml) was treated with sodium 2-ethylhexanoate (SEH, 1.0 M solution in EtOAc, 10 ml) and the mixture was diluted with EtOAc (150 ml) to precipitate the crude product of 7 (2.27 g), which was purified by preparative HPLC [System 500, Waters PrepPAK-500/C18; eluted with MeOH -0.01 M phosphate buffer (pH 7), 15:85] to afford two fractions.
The fraction containing the desired product (the second fraction) was evaporated to a small volume and charged on an Diaion HP-20 column (150 ml), which was washed with H2O (1,000 ml) and then eluted with 50% aq MeOHH. The UV-positive fractions were collected and evaporated to a small volume and lyophilized to afford BMY-28142 (7,573 mg, 22% from IVb) as a colorless powder: MP 150°C (dec); IR vKBrmax cm-1 1770, 1615; UV alma, (pH 7 phosphate buffer) nm (e) 235 (16, From the first fraction, the d2 isomer was isolated after a similar work-up procedure to that described above. Yield, 250 mg (10 % from IVb): MP 140°C (dec); IR vKBrmax cm-1 1755, 1610; UV 2_ max (pH 7 phosphate buffer) nm (e) 234 (16, Method B: To an ice-cooled solution of pyrrolidine (0.12 ml, 1.44 mmol) in H2O (30 ml) was added a solution of the 3-iodomethyl compound IVb (610 mg, 0.65 mmol) in acetone (6 ml) and the mixture was stirred at 0°C for 2 hours and then at room temp for 3 hours. After addition of 1 N HCl (5 ml), the mixture was extracted with EtOAc (3 x 30 ml). The combined extracts were washed with satd aq NaHCO, and NaCl solutions, successively, dried and evaporated. The residual syrup, (crude Vllb, 573 mg) was dissolved in a mixture of THE (6 ml) and diisopropylether (IPE, 6 ml) and 1986 then treated with methyl iodide (6 ml) at room temp overnight. To the mixture was added IPE (50 ml) to give a precipitate, which was collected by filtration to afford the quaternized product Vb (484 mg, 73 % from IVb). The crude compound Vb (484 mg) was deblocked with 90 % TFA to give the TFA salt of 7 (336 mg) as a mixture of d3 and d2 isomer in the ratio of 2.5: 1. This sample was purified by the similar procedure described before to afford the final product 7 (48 mg, 17 % from IVb), which was identical with the sample prepared by Method A.
Method C: A mixture of the 3-iodomethyl compound (IVb) (1.10 g, 1.19 mmol) and m-chloroperbenzoic acid (322 mg, 1.30 mmol) in CH2Cl2 (22 ml) was stirred at 0°C for 15 minutes, poured into H2O (50 ml), and then extracted with CHCl3 (3 x 50 ml). The combined extracts were washed with satd aq NaHCO3 (50 ml) and NaCl3 successively, dried and evaporated to afford the sulfoxide VIIIb A mixture of VIIIb (500 mg, 0.53 mmol) and N-methylpyrrolidine (0.11 ml, 1.06 mmol) in EtOAc (5 ml) was stirred at room temp for 20 minutes. To the mixture was added IPE (50 ml) and the pre- To an ice-cooled solution of IXb (490 mg, 0.47 mmol) in dry acetone (9.8 ml) were added KI (315 mg, 1.90 mmol) and acetyl chloride (AcCl, 67.5 Eel, 0.95 mmol) and the mixture was stirred at 0°C for 2 hours, meanwhile the same amount of KI and AcCl were added 3 times at 30 minutes intervals. The mixture was slowly added to a stirred 0.1 M aq solution of sodium metabisulfite (Na2S2O5, 100 ml). The precipitate formed was collected by filtration and washed with H2O, dried over P,O5 under reduced pressure to give Vb (483 mg, quantitative), which was treated with 90 % TFA (5 ml) at room temp for 1 hour. The reaction mixture was evaporated under reduced pressure below 30°C. The residue was triturated with IPE to give the TFA salt of 7 (282 mg), which was dissolved in MeOH (5 ml). The insoluble material was filtered off and washed with MeOH. The combined filtrate and washings were evaporated to ca. 3 ml and then treated with SEH (1 M solution in EtOAc, 0.95 ml) at room temp for 15 minutes. After the addition of EtOAc (50 ml), the precipitate was collected by filtration to give the crude sample of 7 (233 mg). HPLC analysis showed that this sample was 42 pure, together with the corresponding ]-oxide compound (3.6%), but no 42 isomer. Purification of the product by HPLC [Lichrosorb RP-18, 8 x 300 mm, eluted with 0.01 M ammonium phosphate buffer (pH 7.2) containing 10% MeOH], followed by removal of inorganic salt by HPLC (the same column as that described above, eluted with 10% aq MeOH) afforded BMY-28142 (69 mg, 30%o from IVb) as a colorless powder, which was identical with the product obtained by Method A.
Alternative Preparation of BMY-28142 (7) (Scheme 2) Diphenylmethyl 7-Benzylideneamino-3-chloromethyl-3-cephem-4-carboxylate (X) To a stirred suspension of diphenylmethyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride") (II, 50 g, 0.11 mol) in EtOAc (400 ml) and H2O (150 ml) was added 1 M NaOH (200 ml) under cooling on an ice-water bath. Stirring was continued for 30 minutes to give a clear twophase solution. The EtOAc layer was separated, washed with H2O (300 ml) and dried over anhydrous Na2SO4 (100 g). The EtOAc solution (without removing Na2SO4) was mixed with benzaldehyde (14.2 g, 0.13 mol) and the mixture was stirred for 2 hours at room temp. The insoluble material (Na2SO4) was filtered off. The filtrate was concentrated under reduced pressure. To the concentrate (200 ml) was added n-heptane (400 ml) to precipitate 47.6 g (86 %) of the crystalline product X, which was collected by filtration. The filtrate was concentrated to about 100 ml and treated with n-heptane (300 ml) to give 4.6 g (8 %) of the second crop. To a solution of X (52 g, 0.10 mol) in carbon tetrachloride (1 liter) was added dropwise a solution of NaI (18.6 g, 0.12 mol) in acetone (200 ml) under stirring. After the addition was completed, the mixture was stirred for 40 minutes at room temp and filtered through a Dicalite pad. The filtrate was washed consecutively with satd solution of Na,S,03 (750 ml) and NaC1 (2 x 700 ml), dried over anhydrous Na2SO, (100 g) and filtered. A part of the filtrate was evaporated to dryness to afford the 3-iodomethyl compound XI, which was unstable when kept at room temp for several days. A major part of the filtrate obtained above was used for the next step without isolation of XI. To the chilled (0°C) and stirred filtrate was added dropwise over a period of 30 minutes a solution of N-methylpyrrolidine (11.8 ml, 0.11 mol) in carbon tetrachloride (50 ml). The mixture was stirred for additional 1 hour at 0-5°C to afford a precipitate, which was collected by filtration, washed with carbon tetrachloride (300 ml) and dried over P,O, in vacuo to give 70 g of compound XH: MP 120°C (dec); 111 NMR (60 MHz, CDCl3) 8 ca. 7-Amino-3-(1-methylpyrrolidinio)methyl-3-cephem-4-carboxylate Hydrochloride (XIII) A mixture of XH (68 g, 60 % pure), 98 % formic acid (68 ml) and coned HC1 (42 ml) was stirred at room temp for 1 hour and then poured into acetone (2.5 liters) under vigorous stirring. The precipitate formed was collected by filtration and dried to give a hygroscopic solid (30 g), which was dissolved in H2O (300 ml) and then crystallized by adding acetone (1.5 liters) to afford 13.7 g (yield, 37% from X) of compound XIII as colorless prisms: MP 165°C (dec); IR vgBx cm-13400, 1800, 1595; UV ).ma,x (pH 7 phosphate buffer) nm (e) 267 (9,000); 1H NMR (60 MHz, D2O) 8 
BMY-28142 Sulfate
To a stirred mixture of compound XIII (13.7 g, 37 mmol) in H2O (140 ml) and DMF (280 ml) was added NaHCO3 (6.2 g, 74 mmol) portionwise under ice cooling to give a clear solution within 5 minutes. To the mixture was added the active ester (XIV) 27) (17.7 g, 55.5 mmol) and the mixture was stirred at room temp for 1 hour and then acidified to pH 3 with 4 N H2SO, (5 ml). The insolubles were filtered off and washed with H2O (10 ml). The filtrate and the washings were combined and poured into acetone (3 liters) under vigorous stirring to give a precipitate, which was collected by filtration and dried to give crude BMY-28142 (7, 20.6 g, 85 % pure by HPLC). To a solution of the crude product in H2O (120 ml) was added 4 N H2SO, (40 ml). The mixture was seeded with a few crystalline pieces of BMY-28142 sulfate and kept in a refrigerator for 2 hours to afford cyrstalline powder, which was collected by filtration, washed with I N H2SO, (40 ml) and acetone (200 ml), successively, and dried to afford 15.0 g (70%) of BMY-28142 sulfate: MP 210°C (dec); IR vKBrmax cm-1 1795, 1650; UV 2maa (pH 7 phosphate buffer) nm (e) 236 (17, 200) 
